Negative Regulation of NEDD8 Conjugation Pathway by Novel Molecules and Agents for Anticancer Therapy

E-ISSN： 1873-4286|19|22|4131-4139

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.19, Iss.22, 2013-07, pp. : 4131-4139

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy

By Nawrocki Steffan T Griffin Patrick Kelly Kevin R Carew Jennifer S

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 10, 2012-10 ,pp. : 1563-1573

Informa Healthcare

Access to resources Recommend Favorite

Novel Agents in Anticancer Drug Therapy I (Antiangiogenic Agents, Egfr Inhibitors)

Medicinal Chemistry Reviews - Online, Vol. 2, Iss. 6, 2005-12 ,pp. : 489-494

Bentham Science Publishers

Access to resources Recommend Favorite

A SAR Study: Evaluation of Bromo Derivatives of 8-Substituted Quinolines as Novel Anticancer Agents

Letters in Drug Design & Discovery, Vol. 14, Iss. 12, 2017-10 ,pp. : 1415-1424

Bentham Science Publishers

Access to resources Recommend Favorite

Anti-Cancer Therapy: Targeting the Mevalonate Pathway

Current Cancer Drug Targets, Vol. 6, Iss. 1, 2006-02 ,pp. : 15-37

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting the Mevalonate Pathway for Improved Anticancer Therapy

Current Cancer Drug Targets, Vol. 9, Iss. 5, 2009-08 ,pp. : 626-638

Bentham Science Publishers

Access to resources Recommend Favorite